News

Leading infectious disease researchers called for a coordinated response to HIV and COVID-19 globally in new perspective piece published in The Journal of the American Medical Association.

The PLOS ONE study demonstrates community engagement efforts are critical to ensuring the equitable inclusion of BIPOC communities in vaccine clinical trials.

Prevent COVID U study has expanded to enroll young adults ages 18-29 beyond the university setting and include people who prefer not to receive a vaccine.

Marco Castro-Bojorquez, member of the COVID-19 Prevention Network’s (CoVPN) Community Working Group, has passed away.

The Prevent COVID U is a new clinical study and will test if the Moderna COVID-19 vaccine prevents infection and spread of the Coronavirus among college students.

The release of the faith initiative and diversity report provides a snapshot of key work to build trust and engage the communities hit hardest by the pandemic.

The monoclonal antibody evaluated in a phase 3 trial significantly reduces the risk of contracting symptomatic COVID-19 and reduces the course in study participants.

Interim review NIH-Moderna COVID-19 vaccine shows efficacy rate of 94.5%

Fred Hutch is optimistic about the interim analysis of the Phase 3 trial of the mRNA vaccine candidate developed by Moderna to prevent COVID-19.

Moderna's COVID-19 vaccine Phase 3 study met statistical criteria with a vaccine efficacy of 94.5%.

The CoVPN 5001 study is the first led under the COVID-19 Prevention Network to understand early SARS-CoV-2 infection and the body’s immune responses to the virus that causes COVID-19.

Fred Hutchinson has been named the coordinating center for vaccine clinical trials of the COVID-19 Prevention Network with operations across a network of at least five clinical trials with 100+ international trial sites.

HVTN and HPTN have begun their first clinical trial in response to COVID-19. The study spans clinical trial sites across North and South America.